ERBB2 and breast cancer: Preliminary results from a phase II trial evaluating the effectiveness of the combination of tucatinib-trastuzumab-capecitabine in the treatment of NM from HER2+ breast cancer have reported a median OS of 11.9 months in a cohort of 17 patients (NCT03501979) [72].